Goldman Sachs Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $69

Bristol-Myers Squibb Company -2.21% Pre

Bristol-Myers Squibb Company

BMY

50.52

50.52

-2.21%

0.00% Pre

Goldman Sachs analyst Chris Shibutani maintains Bristol-Myers Squibb (NYSE: BMY) with a Buy and lowers the price target from $81 to $69.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via